Methods of treating breast cancer

Abstract

Provided herein are methods, compounds, and compositions for reducing expression of a MaTAR in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate breast cancer in an individual in need.

1 - 26 . (canceled) 
     
     
         27 . A compound comprising a nucleic acid having a nucleobase sequence that is at least 90% complementary to a Mammary Tumor Associated RNA (MaTAR). 
     
     
         28 . (canceled) 
     
     
         29 . The compound of  claim 27 , wherein the nucleic acid comprises a modified oligonucleotide. 
     
     
         30 . The compound of  claim 29 , wherein the modified oligonucleotide comprises a nucleobase sequence that is at least 90% complementary, at least 95% complementary, or 100% complementary to an equal length portion of the nucleobase sequence selected from SEQ ID Nos: 1-111 and 193-280. 
     
     
         31 . The compound of  claim 30 , wherein the modified oligonucleotide is single-stranded. 
     
     
         32 . The compound of  claim 30 , wherein the modified oligonucleotide is double-stranded. 
     
     
         33 . The compound of  claim 30 , wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides. 
     
     
         34 . The compound of  claim 30 , wherein the modified oligonucleotide comprises a portion of at least 8 contiguous nucleobases of the nucleobase sequence selected from SEQ ID Nos: 112-156 and SEQ ID Nos: 169-192. 
     
     
         35 . The compound of  claim 30 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage, at least one modified sugar moiety, or at least one modified nucleobase, or a combination thereof. 
     
     
         36 . The compound of  claim 35 , wherein the at least one modified internucleoside linkage of the modified oligonucleotide is a phosphorothioate internucleoside linkage. 
     
     
         37 . The compound of  claim 35 , wherein the at least one modified sugar moiety is a bicyclic sugar or 2′-O-methyoxyethyl. 
     
     
         38 . The compound of  claim 35 , wherein the at least one modified nucleobase is a 5-methylcytosine. 
     
     
         39 . The compound of  claim 30 , wherein the modified oligonucleotide comprises:
 a gap segment consisting of linked deoxynucleosides;   a 5′ wing segment consisting of linked nucleosides; and   a 3′ wing segment consisting of linked nucleosides,   wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment, and wherein each nucleoside of each wing segment comprises a modified sugar.   
     
     
         40 - 52 . (canceled)